Trial Endpoints for Aspergillus and Rare Molds: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology
Year: 2026
Type: article
Abstract: BACKGROUND: Invasive mold disease (IMD) remains a substantial cause of patient morbidity and mortality. Aspergillosis and mucormycosis remain the predominant infections encountered, although rare molds continue to emerge as important pathogens. Improvement in patient outcomes has been the result of progress in risk stratification, diagnostics, supportive care, antifungal therapy, and/or prophylaxis, yet substantial challenges remain, requiring the development of novel treatment strategies. Clinical trials evaluating treatment response are currently based on consensus criteria published in 2008. However, advances in clinical mycology and the broadening variety of mold diseases in clinical trials necessitate a revision of these criteria to ensure that adjudication of patient outcomes accurately captures responses to therapeutic intervention. METHODS: To tackle this task, an international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened. RESULTS: The panel produced updated consensus guidance for assessing treatment responses and defining study outcomes in clinical trials of IMD in both adults and children. CONCLUSIONS: Along with guidance, potential pitfalls in assessing outcome, such as discordant clinical, radiologic, and/or mycologic data and areas for future research are discussed.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag580
Authors: Martin Hoenigl, George R Thompson, Jessica S Little, Bart J Rijnders, Ritesh Agarwal, Oliver A Cornely, Jean-Pierre Gangneux, Dimitrios P Kontoyiannis, Cornelia Lass-Flörl, Johan Maertens, Marcio Nucci, Peter G Pappas, Matthew Goon, Emmanuel Roilides, Thomas J Walsh, Carolynn T Jones, Gerald McGwin, Thomas F Patterson, Luis Ostrosky-Zeichner, Monica A Slavin
Institutions: Medical University of Graz, BioTechMed-Graz, University of California Davis Medical Center, University of California, Davis, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Erasmus MC, Post Graduate Institute of Medical Education and Research, University of Cologne, German Center for Infection Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Inserm, École des Hautes Études en Santé Publique, Institut de Recherche en Santé, Environnement et Travail, Centre Hospitalier Universitaire de Rennes, Université de Rennes, The University of Texas MD Anderson Cancer Center, Innsbruck Medical University, Universität Innsbruck, Universitair Ziekenhuis Leuven, KU Leuven, Universidade Federal do Rio de Janeiro, University of Alabama at Birmingham, UAB Medicine, Aristotle University of Thessaloniki, Ippokrateio General Hospital of Thessaloniki, University of Maryland, Baltimore, The Ohio State University, The University of Texas at San Antonio Health Science Center, The University of Texas Health Science Center at Houston, The University of Melbourne, Peter MacCallum Cancer Centre
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
OpenAlex ID: W7234772168
